# FDA Type II Drug Master File (API)

> Draft and self-check Type II API Drug Master Files in FDA eCTD Module 3 format with Module 1 administrative documents, LoA, annual report, deficiency response, and completeness-assessment support.



Tags: FDA, DMF, eCTD, CMC, API, GDUFA, Regulatory


## Example Prompts

- Draft a Type II API DMF in eCTD Module 3 format
- Create a DMF LoA and annual report template
- Check a Type II DMF package for completeness gaps

URL: https://rakenne.app/skills/fda-drug-master-file-type-ii/index.md

Try this skill: https://rakenne.app/a/?skill=fda-drug-master-file-type-ii


## Overview

Draft and self-check Type II API Drug Master Files in FDA eCTD Module 3 format with Module 1 administrative documents, LoA, annual report, deficiency response, and completeness-assessment support.

## What It Covers

- Module 1 administrative documents, including cover letter, administrative information, statement of commitment, LoA template, and environmental assessment / categorical exclusion placeholder.
- Full ICH M4Q Module 3.2.S drug substance structure: S.1 general information through S.7 stability.
- DMF lifecycle templates for annual reports, deficiency responses, and closure / inactivation letters.
- FDA Type II API DMF completeness-screening themes: GDUFA / AFR status, holder obligations, site details, process controls, impurity controls, specifications, analytical validation, batch analyses, and stability commitments.

## Example Conversation

> **You:** We manufacture an API in Gujarat and need a first FDA Type II DMF for ANDA customers. We have process flow, specs, 3 validation batches, impurity data, and 12 months stability, but no DMF number yet.

> **Agent:** I’ll scaffold the Type II API DMF as an eCTD-oriented package. I’ll keep the DMF number, FEI/DUNS/UEI, Form FDA 3938 metadata, and AFR status as placeholders until you provide source evidence.

> **Agent:** I’ll create Module 1 administrative drafts, Module 3.2.S.1–S.7 files in ICH M4Q order, lifecycle templates, and a completeness-assessment checklist. I’ll also keep restricted manufacturing details inside the DMF and use the LoA only to authorize FDA reference by your ANDA customers.

> **Agent:** Draft package created. Next I’ll run `fda_type_ii_dmf_completeness_checker` against the dossier and summarize required gaps before your CMC/regulatory review.

<!-- end example conversation -->

## Sample Output Excerpt

Excerpt from a generated Type II API DMF scaffold.

---

```markdown
# FDA Type II Drug Master File — [API Name]

## File Manifest

### Module 1

- m1/1.2-cover-letter.md
- m1/1.3.1-administrative-information.md
- m1/1.3.3-statement-of-commitment.md
- m1/1.4.1-letter-of-authorization-template.md
- m1/1.12.14-environmental-assessment-or-categorical-exclusion.md

### Module 3 — 3.2.S Drug Substance

- m3/3.2.S.1-general-information.md
- m3/3.2.S.2-manufacture.md
- m3/3.2.S.3-characterisation.md
- m3/3.2.S.4-control-of-drug-substance.md
- m3/3.2.S.5-reference-standards.md
- m3/3.2.S.6-container-closure-system.md
- m3/3.2.S.7-stability.md

## 3.2.S.3.2 Impurities — Draft Notes

- Organic impurities: [source table / method / limits]
- Residual solvents: [ICH Q3C classification and controls]
- Elemental impurities: [ICH Q3D risk assessment reference]
- Mutagenic / nitrosamine risk: [assessment status and data location]

## Open Regulatory Placeholders

- DMF number: [not assigned]
- GDUFA Type II API DMF fee status: [provide payment evidence]
- Available for Reference status: [do not claim until FDA confirms]
```

<!-- /excerpt -->

## Extension Tools

**`fda_type_ii_dmf_completeness_checker`** checks a dossier directory or compiled draft for required Type II API DMF signals:

- Module 1 administrative documents: cover letter, administrative information, statement of commitment, Letter of Authorization template, and environmental assessment / categorical exclusion placeholder.
- Module 3.2.S coverage: S.1 general information, S.2 manufacture, S.3 characterization, S.4 control of drug substance, S.5 reference standards, S.6 container closure, and S.7 stability.
- FDA / ICH content signals: 21 CFR 314.420 obligations, GDUFA / AFR context, authorized parties, manufacturing sites, process controls, material controls, process validation, specifications, analytical validation, batch analyses, stability data, and eCTD lifecycle awareness.
- Granular impurity coverage: organic impurities, residual solvents, elemental impurities, and mutagenic / nitrosamine risk are checked separately.

Run the checker before final review, resolve failed items, then perform expert CMC/regulatory review and eCTD technical validation before submission.

## Getting Started

Add your source materials to the workspace: API identity, holder and site details, process narrative, control strategy, specifications, analytical methods, validation summaries, batch analyses, impurity assessments, stability data, authorized-party list, and any FDA correspondence. Then activate the skill and ask it to draft an initial DMF, annual report, LoA, or deficiency response.



---

Back to [Skill Library](https://rakenne.app/skills/index.md)